90 results about "Syringic acid" patented technology

The present invention relates to a compound of the formula: R-AR—O—Y—R′Wherein R represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid, —NO2, —NH2, —NHCOCH3, and —NH—Y—R′, which is attached directly to AR or attached through an aliphatic chain. The carboxylic acid moiety in R includes but is not limited to the following carboxylic acids: benzoic acids, cinnamic acids, ferulic acid, caffeic acid, syringic acid, salicylic acid, vanillic acid, phenylacetic acids, phenylpropionic acids, and sinapinic acid. -AR—O— is a biologically active phenolic moiety comprising 1 to 6 substituted or unsubstituted aryl rings that are directly bonded to each other, fused together, or joined through a linking group. Y represents a member selected from: —COCH2O— (glycolic ester moiety) —COCH(CH3)O— (lactic ester moiety) —COCH2OCH2CH2O— (dioxanone ester moiety) —COCH2CH2CH2CH2CH2O— (caprolactone ester moiety) —CO(CH2)mO— where m is an integer between 2-4 and 6-24 inclusive —COCH2O(CH2CH2O)n— where n is an integer between 2 and 24, inclusive; and R′ is either hydrogen or a benzyl or an alkyl group, the alkyl group being either straight-chained or branched. The resultant functionalized phenolic compounds, used singly or in combinations, and their polymers have controllable degradation profiles, releasing the active component over a desired time range. The polymers are useful for biomaterials and biomedical devices, wherein said biologically active phenolic moiety is a residue of a phenolic compound.

The invention discloses a synthesis method of bioactive derivative bagasse xylan syringic acid ester-g-AM. The synthesis method comprises the following steps: by taking bagasse xylan as a starting rawmaterial, taking ammonium persulfate as an initiator, taking N,N'-methylene bisacrylamide as a crosslinking agent, preparing bagasse xylan-g-AM in a water-phase solution; then by taking the bagasse xylan-g-AM as a raw material, taking syringic acid as an esterifying agent and taking the ammonium persulfate as a catalyst, preparing the bagasse xylan syringic acid ester-g-AM in a solvent N,N-dimethylacetamide (DMA). A product prepared through the synthesis method is esterified on the basis of grafting, and a finally synthesized product, namely the bagasse xylan syringic acid ester-g-AM, improves the problem of low water solubility of the bagasse xylan and also expands the application field of the bagasse xylan. Meanwhile, by the introduction of active groups of acrylamide (AM) and the syringic acid, the bioactivity of the bagasse xylan is further improved.

Dry milling methods for preparing oat products enriched in the content of β-glucan and methods for preparing foodstuffs incorporating such an enriched oat product especially ready-to-eat cereals are provided. Heat conditioned dehulled oats are dry milled to form a coarse whole non defatted oat flour and then, without a preceding removal of fat, dry fractionated into coarser bran and finer oat flour fractions at multiple stages. The coarse oat flour is first dry classified to separate or form a coarser fraction oat bran containing more concentrated β-glucan and a finer oat flour or starch containing or endosperm containing fraction. The oat bran is subjected to second and third rounds of milling and classification to form a high β-glucan content (>7-9%) oat bran and a low β-glucan content (3%) oat flour. The methods are low cost and commercially practical. Preferably, the high β-glucan content oat bran and oat flour fractions can have a syringic acid to ferulic acid ratio of at least 2.5:1 indicating improved flavor. Preferably, the oat bran and oat flour have a Farinograph value of 5 to 20 minutes indicated partial gelatinization. The oat bran and oat flours can be used to prepare foodstuffs such as ready-to-eat cereals.

The invention relates to a synthesis method of 5, 7, 4'-trihydroxy-3', 5'-dimethoxyflavone and application thereof, particularly to a chemical synthesis method of allelochemicals, 5, 7, 4'-trihydroxy-3', 5'-dimethoxyflavone, by separating from allelochemical rice, Oryza sativa L.(PI312777). Syringic acid and phloroglucinol are used as the raw materials, the object products are synthesized by four steps. The products are protected by benzyl, and benzyl is synchronously removed with glacial acetic acid heating and ring closing in the final reaction step, thereby reducing the reaction steps. Compared with the method of removing benzyl by Pd / C charging hydrogen, the method of the invention is more simple, economical, and safe. The invention is capable of effectively stopping growth of garnyardgrass, cyperus iria linn and cyperus difformis linn seeds in rice, restraining paddyfield weed, improving rice yield, stopping spore germination of pyricularia oryzae and rhizoctonia solan so as to avoid the problems due to pesticide application and promote sustainable development of agriculture.

Dry milling methods for preparing oat products enriched in the content of β-glucan and methods for preparing foodstuffs incorporating such an enriched oat product especially ready-to-eat cereals are provided. Heat conditioned dehulled oats are dry milled to form a coarse whole non defatted oat flour and then, without a preceding removal of fat, dry fractionated into coarser bran and finer oat flour fractions at multiple stages. The coarse oat flour is first dry classified to separate or form a coarser fraction oat bran containing more concentrated β-glucan and a finer oat flour or starch containing or endosperm containing fraction. The oat bran is fractionated into a coarse and fine oat bran sub-streams. The oat bran sub-streams are each is subjected to second roller milling step and then bolted. The second bolting of oat bran is then subjected to a third round of milling and classification to form a high β-glucan content (>7-9%) oat bran and a low β-glucan content (3%) oat flour. The methods are low cost and commercially practical. Preferably, the high β-glucan content oat bran and oat flour fractions can have a syringic acid to ferulic acid ratio of at least 2.5:1 indicating improved flavor. Preferably, the oat bran and oat flour have a Farinograph value of 5 to 20 minutes indicated partial gelatinization. The oat bran and oat flours can be used to prepare foodstuffs such as ready-to-eat cereals.

The invention discloses application of a phenolic acid compounds in preparation of bleeding stopping and stasis eliminating medicaments. The phenolic acid compounds mainly comprise chlorogenic acid, caffeic acid, coumaricacid, vanillic acid, cinnamic acid, syringic acid, protocatechuric acid, gallic acid, ferulic acid, p-hydroxybenzoic acid, hydroquinone or pyrocatechol and medicinal salts thereof. Experiments show that the phenolic acid compounds have the functions of stopping blood and eliminating stasis; one or more of the active ingredients is applied to preparing the bleeding stopping and stasis eliminating medicaments which are used for preventing and treating menorrhagia, artificial abortion, postpartum hemorrhage and dysfunctional uterine bleeding of women.

Dry milling methods for preparing oat products enriched in the content of β-glucan and methods for preparing foodstuffs incorporating such an enriched oat product especially ready-to-eat cereals are provided. Heat conditioned dehulled oats are dry milled to form a coarse whole non defatted oat flour and then, without a preceding removal of fat, dry fractionated into coarser bran and finer oat flour fractions at multiple stages. The coarse oat flour is first dry classified to separate or form a coarser fraction oat bran containing more concentrated β-glucan and a finer oat flour or starch containing or endosperm containing fraction. The oat bran is fractionated into a coarse and fine oat bran sub-streams. The oat bran sub-streams are each is subjected to second roller milling step and then bolted. The second bolting of oat bran is then subjected to a third round of milling and classification to form a high β-glucan content (>7-9%) oat bran and a low β-glucan content (3%) oat flour. The methods are low cost and commercially practical. Preferably, the high β-glucan content oat bran and oat flour fractions can have a syringic acid to ferulic acid ratio of at least 2.5:1 indicating improved flavor. Preferably, the oat bran and oat flour have a Farinograph value of 5 to 20 minutes indicated partial gelatinization. The oat bran and oat flours can be used to prepare foodstuffs such as ready-to-eat cereals.

The invention relates to a juglans mandshurica husk extractive which contains the main medical active ingredients of 8-hydroxyl-9,10-anthraquinone-1-carboxylic acid, REG IOLONE, 4,5,8- trihydroxy-alpha-naphthyl ketone-3-O-beta-D-glucopyranoside, 4,5,8- trihydroxy-alpha- naphthyl ketone-3-O-(6'-O- nutgall acyl)-beta-D- glucopyranoside, 1-(4'- hydroxyl phenyl)-7-(3''-methoxy-4''-hydroxyl phenyl) heptane-3-alcohol, 4-hydroxy-2,6- syringol-1-O-beta-D-glucopyranoside, 4- hydroxyl-2,6- syringol-1-O-(6'-O- nutgall acyl)-beta-D- glucopyranoside, vanillic acid-4-O-(6'-O- nutgall acyl)-beta-D-glucopyranoside, vanillic aldehyde, vanillic acid, gallic acid, syringic acid, kaempferol, quercetin glycoside, myrica rubra and quercetin. The juglans mandshurica husk extractive has good effect in curing hepatopathy and restraining the growth of tumor and especially has the effect of directly killing the hepatocarcinoma cells.

The present invention relates to a compound of the formula:R-AR—O—Y—R′Wherein R represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid, —NO2, —NH2, —NHCOCH3, and —NH—Y—R′, which is attached directly to AR or attached through an aliphatic chain. The carboxylic acid moiety in R includes but is not limited to the following carboxylic acids: benzoic acids, cinnamic acids, ferulic acid, caffeic acid, syringic acid, salicylic acid, vanillic acid, phenylacetic acids, phenylpropionic acids, and sinapinic acid.-AR—O— is a biologically active phenolic moiety comprising 1 to 6 substituted or unsubstituted aryl rings that are directly bonded to each other, fused together, or joined through a linking group.Y represents a member selected from:—COCH2O— (glycolic ester moiety)—COCH(CH3)O— (lactic ester moiety)—COCH2OCH2CH2O— (dioxanone ester moiety)—COCH2CH2CH2CH2CH2O— (caprolactone ester moiety)—CO(CH2)mO— where m is an integer between 2-4 and 6-24 inclusive—COCH2O(CH2CH2O)n— where n is an integer between 2 and 24, inclusive; andR′ is either hydrogen or a benzyl or an alkyl group, the alkyl group being either straight-chained or branched.The resultant functionalized phenolic compounds, used singly or in combinations, and their polymers have controllable degradation profiles, releasing the active component over a desired time range. The polymers are useful for biomaterials and biomedical devices, wherein said biologically active phenolic moiety is a residue of a phenolic compound.

The invention discloses a compound nanometer preparation for treating the diabetes mellitus type 2 and a preparation method thereof. The compound nanometer preparation for treating the diabetes mellitus type 2 is mainly prepared from, by weight, 8-15 parts of aloe acetylation gulcomannan, 3-6 parts of Cicletanine, 1-2 parts of decanoyl acetaldehyde, 4-8 parts of syringaresinol monoglucoside, 5-20 parts of banana leaf powder, 3-7 parts of grapefruit seed extract, 1-4 parts of sodium ethylene diamine tetracetate, 0.8-2.0 parts of myristic acid, 0.1-0.5 part of syringic acid, 0.1-0.3 part of gentisic acid, 3-10 parts of lysine, 1-3 parts of carotenoid and 0.03-0.1 part of antioxidant. According to the compound nanometer preparation, blood glucose rising is controlled through interaction of various ingredients, the blood pressure and blood fat of a patient suffering from the diabetes mellitus type 2 are adjusted, sufficient nutritional ingredients can be provided for the patient suffering from the diabetes mellitus type 2, the immunity of the patient is improved, diabetes mellitus and arteriosclerosis are relieved, the effect of treating the diabetes mellitus type 2 is remarkable, and the side effect is small.

A Tropaeolum majus effervescent tablet consisting of Tropaeolum majus powder, coixol, syringic acid, sorbitol, xanthan gum, sodium citrate, and sodium bicarbonate. The different components of the Tropaeolum majus effervescent tablet coordinate and achieve the effects of clearing heat, activating blood, resolving stasis, removing toxin and inflammation, and relieving pain. The present invention has treatment effects on idiopathic pulmonary fibrosis and reduces the suffering of idiopathic pulmonary fibrosis patients.